http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1261602-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2b9dc89cc4ba060cc73bbf0c90bbb78 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
filingDate | 2001-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2004-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bce3fc739316ccf61e77d732f50fd47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1111e9e60b5815c4276e73bc4e648051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_095f5b579f99fb0d66bdea743b577dbd |
publicationDate | 2004-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1261602-B1 |
titleOfInvention | Imidazol-2-carboxamide derivatives as raf kinase inhibitors |
abstract | Compounds of formula (I): wherein X is O, CH<SUB>2</SUB>, S or NH, or the moiety X-R<SUP>1 </SUP>is hydrogen; V is CH or N; R<SUP>1 </SUP>is hydrogen, C<SUB>1-6</SUB>alkyl, C<SUB>3-7</SUB>cycloalkyl, aryl, arylC<SUB>1-6</SUB>alkyl, heterocyclyl, heterocyclyl-C<SUB>1-6</SUB>alkyl, heteroaryl, or heteroarylC<SUB>1-6</SUB>alkyl any of which except hydrogen may be optionally substituted; R<SUP>2 </SUP>and R<SUP>3 </SUP>independently represent hydrogen, C<SUB>1-6</SUB>alkyl, C<SUB>3-7</SUB>cycloalkyl, aryl, arylC<SUB>1-6</SUB>alkyl, heteroaryl, heteroarylC<SUB>1-6</SUB>alkyl, heterocyclyl, or heterocyclylC<SUB>1-6</SUB>alkyl any one of which except hydrogen may be optionally substituted, or R<SUP>2 </SUP>and R<SUP>3 </SUP>together with the nitrogen atom to which they are attached form a 4- to 10-membered optionally substituted monocyclic or bicyclic ring; Ar is an aryl or heteroaryl ring either of which may be optionally substituted; one of X<SUB>1 </SUB>and X<SUB>2 </SUB>is N and the other is NR<SUP>4</SUP>, wherein R<SUP>4 </SUP>is hydrogen, C<SUB>1-6</SUB>alkyl, or arylC<SUB>1-6</SUB>alkyl; or pharmaceutically acceptable salts thereof; their use as inhibitors of Raf kinases and pharmaceutical compositions containing them. |
priorityDate | 2000-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 194.